Teva Pharmaceutical Industries Ltd. (TEVA) intrinsic value & 10-year financials
Teva Pharmaceutical Industries Ltd. (TEVA) has a Graham intrinsic value of $40.19 per share. At $41.50 on Oct 17, 2026, the stock trades 3% above that value. Over the last 10 fiscal years revenue shrank 2.6% a year to $17.3B, with an average return on invested capital of -2.7%.
- Graham intrinsic value
- $40.19
- Share price (Oct 17, 2026)
- $41.50
- Price vs Graham value
- 3% above
- Market cap
- $48.3B
- Revenue (FY2025)
- $17.3B
- Revenue growth (10-yr CAGR)
- -2.6%
- ROIC (10-yr avg)
- -2.7%
- Free cash flow (FY2025)
- $1.1B
TEVA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $17.3B | $1.4B | $1.21 | $1.1B | 12.5% | 40.8% |
| FY2024 | $16.5B | -$1.6B | -$1.45 | $749.0M | -1.8% | -5.8% |
| FY2023 | $15.8B | -$559.0M | -$0.50 | $842.0M | 2.7% | 6.2% |
| FY2022 | $14.9B | -$2.4B | -$2.12 | $1.0B | -14.1% | -18.9% |
| FY2021 | $15.9B | $417.0M | $0.38 | $236.0M | 10.8% | 10.9% |
| FY2020 | $16.7B | -$4.0B | -$3.64 | $638.0M | -21.4% | -27.1% |
| FY2019 | $16.9B | -$999.0M | -$0.91 | $223.0M | -2.6% | -2.4% |
| FY2018 | $18.9B | -$2.1B | -$0.00 | $1.8B | -8.7% | -4.8% |
| FY2017 | $22.4B | -$16.3B | -$0.00 | $2.6B | -78.1% | -27.5% |
| FY2016 | $21.9B | $329.0M | $0.00 | $4.3B | 9.8% | 1.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
TEVA PHARMACEUTICAL INDUSTRIES LTD is facing top-line stagnation, with revenue contracting over the decade.
TEVA PHARMACEUTICAL INDUSTRIES LTD has historically struggled to out-earn its cost of capital, averaging just -2.7% ROIC.
TEVA PHARMACEUTICAL INDUSTRIES LTD has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, TEVA PHARMACEUTICAL INDUSTRIES LTD is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $40.19 per share.